Eliem Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Eliem Therapeutics, Inc. (NASDAQ: ELYM) is a clinical-stage biotechnology company that develops therapies targeting autoimmune-driven inflammatory diseases, with a primary focus on novel CD19-targeted treatments for immune-mediated disorders affecting millions worldwide. The company offers budoprutug (formerly TNT119), an anti-CD19 antibody designed for systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, membranous nephropathy, and other autoimmune conditions; it previously advanced product candidates for neuronal excitability disorders, including ETX-810, a palmitoylethanolamide prodrug for diabetic peripheral neuropathic pain and lumbosacral radicular pain, and ETX-155, a GABA-A receptor positive allosteric modulator for major depressive disorder, hormone-related depression, and photosensitive epilepsy, alongside preclinical Kv7 and GAD programs. Eliem Therapeutics maintains research and development operations in the United States and Cambridge, United Kingdom, targeting patients with unmet needs in immunology, inflammation, chronic pain, psychiatry, and epilepsy. Founded in 2018 and headquartered in Bellevue, Washington, with a registered office in Wilmington, Delaware, the company completed the acquisition of Tenet Medicines, Inc. in June 2024, marking a strategic pivot from neuronal excitability disorders to autoimmune diseases and securing approximately $220 million in cash through a concurrent $120 million private placement with institutional life science investors including RA Capital Management, Boxer Capital, and Janus Henderson Investors to fund operations into 2027 and Phase 2 trials for budoprutug. In October 2024, Eliem Therapeutics announced its rebranding to Climb Bio, Inc., reflecting its sharpened emphasis on immune-mediated diseases following pipeline restructuring and leadership enhancements, including the appointment of Aoife Brennan as CEO, Jan Hillson as Senior Clinical Advisor, Brett Kaplan as Chief Operating Officer, and new board members. The company plans Phase 2 clinical trial initiations for budoprutug by late 2024 or early 2025 and was added to the Russell 2000 and Russell 3000 Indexes in 2024.
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 5.4% – Here’s What Happened
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 6.1% – Should You Buy?
Climb Bio to Host Virtual Investor Event on October 15, 2024
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Eliem Therapeutics Announces Additions to its Leadership Team
Eliem Therapeutics Reports Second Quarter Financial Results
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard